107 related articles for article (PubMed ID: 16178797)
1. Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy.
Sjøholt G; Anensen N; Wergeland L; Mc Cormack E; Bruserud Ø; Gjertsen BT
Curr Drug Targets; 2005 Sep; 6(6):631-46. PubMed ID: 16178797
[TBL] [Abstract][Full Text] [Related]
2. A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia.
Hu CW; Qiu Y; Ligeralde A; Raybon AY; Yoo SY; Coombes KR; Qutub AA; Kornblau SM
Nat Biomed Eng; 2019 Nov; 3(11):889-901. PubMed ID: 30988472
[TBL] [Abstract][Full Text] [Related]
3. Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia.
Forthun RB; Aasebø E; Rasinger JD; Bedringaas SL; Berven F; Selheim F; Bruserud Ø; Gjertsen BT
J Proteomics; 2018 Feb; 173():32-41. PubMed ID: 29175091
[TBL] [Abstract][Full Text] [Related]
4. Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML.
Bruserud Ø; Stapnes C; Tronstad KJ; Ryningen A; Anensen N; Gjertsen BT
Expert Opin Ther Targets; 2006 Feb; 10(1):51-68. PubMed ID: 16441228
[TBL] [Abstract][Full Text] [Related]
5. Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML).
Sjøholt G; Bedringaas SL; Døskeland AP; Gjertsen BT
Curr Pharm Biotechnol; 2006 Jun; 7(3):159-70. PubMed ID: 16789901
[TBL] [Abstract][Full Text] [Related]
6. Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells.
Weber C; Schreiber TB; Daub H
J Proteomics; 2012 Feb; 75(4):1343-56. PubMed ID: 22115753
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective.
van Dijk AD; de Bont ESJM; Kornblau SM
Expert Rev Proteomics; 2020 Jan; 17(1):1-10. PubMed ID: 31945303
[No Abstract] [Full Text] [Related]
8. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
9. Proteomic analysis of acute myeloid leukemia: Identification of potential early biomarkers and therapeutic targets.
López-Pedrera C; Villalba JM; Siendones E; Barbarroja N; Gómez-Díaz C; Rodríguez-Ariza A; Buendía P; Torres A; Velasco F
Proteomics; 2006 Apr; 6 Suppl 1():S293-9. PubMed ID: 16521150
[TBL] [Abstract][Full Text] [Related]
10. Quantitative proteomic analysis of EZH2 inhibition in acute myeloid leukemia reveals the targets and pathways that precede the induction of cell death.
Sandow JJ; Infusini G; Holik AZ; Brumatti G; Averink TV; Ekert PG; Webb AI
Proteomics Clin Appl; 2017 Sep; 11(9-10):. PubMed ID: 28447382
[TBL] [Abstract][Full Text] [Related]
11. Proteomics of p53 in diagnostics and therapy of acute myeloid leukemia.
Anensen N; Haaland I; D'Santos C; Van Belle W; Gjertsen BT
Curr Pharm Biotechnol; 2006 Jun; 7(3):199-207. PubMed ID: 16789904
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
Kurotaki H; Tsushima Y; Nagai K; Yagihashi S
Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673
[TBL] [Abstract][Full Text] [Related]
13. Perspectives of proteomics in acute myeloid leukemia.
Czibere A; Grall F; Aivado M
Expert Rev Anticancer Ther; 2006 Nov; 6(11):1663-75. PubMed ID: 17134369
[TBL] [Abstract][Full Text] [Related]
14. AML1-ETO triggers epigenetic activation of early growth response gene l, inducing apoptosis in t(8;21) acute myeloid leukemia.
Fu L; Huang W; Jing Y; Jiang M; Zhao Y; Shi J; Huang S; Xue X; Zhang Q; Tang J; Dou L; Wang L; Nervi C; Li Y; Yu L
FEBS J; 2014 Feb; 281(4):1123-31. PubMed ID: 24314118
[TBL] [Abstract][Full Text] [Related]
15. Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic Leukemia.
Abramowitz J; Neuman T; Perlman R; Ben-Yehuda D
BMC Med Genomics; 2017 Mar; 10(1):18. PubMed ID: 28340577
[TBL] [Abstract][Full Text] [Related]
16. Specific pattern of protein expression in acute myeloid leukemia harboring FLT3-ITD mutations.
Scholl S; Melle C; Bleul A; Spies-Weisshart B; Kunert C; Höffken K; von Eggeling F
Leuk Lymphoma; 2007 Dec; 48(12):2418-23. PubMed ID: 18067018
[TBL] [Abstract][Full Text] [Related]
17. The IRF9-SIRT1-P53 axis is involved in the growth of human acute myeloid leukemia.
Tian WL; Guo R; Wang F; Jiang ZX; Tang P; Huang YM; Sun L
Exp Cell Res; 2018 Apr; 365(2):185-193. PubMed ID: 29501566
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms and consequences of constitutive activation of integrin-linked kinase in acute myeloid leukemia.
Alasseiri M; Ahmed AU; Williams BRG
Cytokine Growth Factor Rev; 2018 Oct; 43():1-7. PubMed ID: 29903521
[TBL] [Abstract][Full Text] [Related]
19. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.
Han L; Qiu P; Zeng Z; Jorgensen JL; Mak DH; Burks JK; Schober W; McQueen TJ; Cortes J; Tanner SD; Roboz GJ; Kantarjian HM; Kornblau SM; Guzman ML; Andreeff M; Konopleva M
Cytometry A; 2015 Apr; 87(4):346-56. PubMed ID: 25598437
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
